Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 250 of 272 entries
View as:

Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT02231580 Org: User:
Start: 09/01/14 End: 03/31/16 Due: 03/31/17

A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide

Phase: N/A Priority: Normal
NCT ID: NCT00234520 Org: User:
Start: 05/31/03 End: 02/18/05 Due: 02/18/06

Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.

Phase: N/A Priority: Normal
NCT ID: NCT03744585 Org: User:
Start: 11/06/18 End: 07/07/19 Due: 07/07/20

Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

Phase: N/A Priority: Normal
NCT ID: NCT04957160 Org: User:
Start: 09/09/21 End: 06/15/22 Due: 06/15/23

Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice

Phase: N/A Priority: Normal
NCT ID: NCT02454803 Org: User:
Start: 01/31/15 End: 06/03/19 Due: 06/03/20

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Phase: N/A Priority: Normal
NCT ID: NCT00149188 Org: User:
Start: 02/29/04 End: 08/24/05 Due: 08/24/06

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01020448 Org: User:
Start: 11/30/09 End: 06/30/13 Due: 06/30/14

Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity

Phase: N/A Priority: Normal
NCT ID: NCT03017729 Org: User:
Start: 02/10/17 End: 11/30/20 Due: 11/30/21

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Phase: N/A Priority: Normal
NCT ID: NCT02493517 Org: User:
Start: 10/31/14 End: 02/16/17 Due: 02/16/18

A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke

Phase: N/A Priority: Normal
NCT ID: NCT01239628 Org: User:
Start: 12/31/10 End: 12/31/15 Due: 12/31/16

Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)

Phase: N/A Priority: Normal
NCT ID: NCT03689673 Org: User:
Start: 04/24/13 End: 11/16/20 Due: 11/16/21

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Phase: N/A Priority: Normal
NCT ID: NCT04852679 Org: User:
Start: 05/24/21 End: 01/13/23 Due: 01/13/24

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

Phase: N/A Priority: Normal
NCT ID: NCT06937931 Org: User:
Start: 06/30/25 End: 11/30/27 Due: 11/30/28

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Phase: N/A Priority: Normal
NCT ID: NCT00216372 Org: User:
Start: 09/30/03 End: 10/31/08 Due: 10/31/09

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00910091 Org: User:
Start: 08/31/09 End: 07/31/13 Due: 07/31/14

Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia

Phase: N/A Priority: Normal
NCT ID: NCT01753336 Org: User:
Start: 03/31/13 End: 10/31/15 Due: 10/31/16

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Phase: N/A Priority: Normal
NCT ID: NCT00353496 Org: User:
Start: 06/30/06 End: 04/30/13 Due: 04/30/14

Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

Phase: N/A Priority: Normal
NCT ID: NCT00288509 Org: User:
Start: 02/28/06 End: 01/31/08 Due: 01/31/09

Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT04353765 Org: User:
Start: 01/30/20 End: 06/05/20 Due: 06/05/21

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea

Phase: N/A Priority: Normal
NCT ID: NCT00891371 Org: User:
Start: 07/31/09 End: 08/31/13 Due: 08/31/14

Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.

Phase: N/A Priority: Normal
NCT ID: NCT04649632 Org: User:
Start: 04/29/20 End: 09/18/20 Due: 09/18/21

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Phase: N/A Priority: Normal
NCT ID: NCT01562522 Org: User:
Start: 03/31/12 End: 07/31/13 Due: 07/31/14

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Phase: N/A Priority: Normal
NCT ID: NCT02651987 Org: User:
Start: 12/15/15 End: 10/24/19 Due: 10/24/20

Study in Polish Acromegalic Patients Treated With Somatuline Autogel

Phase: N/A Priority: Normal
NCT ID: NCT01333384 Org: User:
Start: 10/31/10 End: 06/30/14 Due: 06/30/15

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00210457 Org: User:
Start: 09/30/00 End: 07/15/02 Due: 07/15/03